
Bain buys Japanese pharma Mitsubishi Tanabe for $3.4bn
Bain Capital has agreed to buy Mitsubishi Tanabe for around $3.4 bn, setting up one of the largest private equity buyouts in Japan's health sector.
Newsletters and Deep Dive digital magazine
Bain Capital has agreed to buy Mitsubishi Tanabe for around $3.4 bn, setting up one of the largest private equity buyouts in Japan's health sector.
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for bronchiectasis in the US.
BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2200 job cuts, adding a target of another $2bn by end-2027.
AstraZeneca's exposure to liability in a Chinese investigation into illegal drug imports appears to be much less than had been feared.
Newel Health has been granted EU certification for its VR-based digital therapeutic for chronic pain, clearing the way for its launch in Europe.
Editor's Picks
Newsletters and Deep Dive
digital magazine